Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.17 USD
+0.78 (0.69%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $113.24 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
by Zacks Equity Research
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
by Zacks Equity Research
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
by Zacks Equity Research
Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Reasons to Hold Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
Align Technology (ALGN) Up 20.5% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
Boston Scientific (BSX) Faces Rising Costs, Competition
by Zacks Equity Research
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Why You Should Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Shockwave Medical's (SWAV) Reducer Receives Positive Results
by Zacks Equity Research
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
Do Options Traders Know Something About Cardinal Health (CAH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cardinal Health (CAH) stock based on the movements in the options market lately.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
by Zacks Equity Research
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.